Moderna CEO Says Cancer Vaccine Could Work Beyond Melanoma But Shares Still Slip

BeInCrypto
Abrir em BeInCrypto
Moderna CEO Says Cancer Vaccine Could Work Beyond Melanoma But Shares Still Slip

Moderna CEO Stéphane Bancel says the personalized cancer vaccine built with Merck could work beyond melanoma. Shares of Moderna (MRNA) still fell as much as 25% after the trial data leaked.

The drop came even though the Phase 3 trial had cut melanoma recurrence or death risk by 42%. The stock had climbed more than 500% in 2026 on hopes for the program.

Can the Cancer Vaccine Work Beyond Melanoma?

On Bloomberg's "The Close," Bancel told Romaine Bostick the therapy should work in more cancers than melanoma. Still, each new tumor type needs its own trial.

"I believe the kidney cancer should look positive."

Stéphane Bancel, CEO of Moderna, in an interview with Bloomberg

https://www.youtube.com/watch?v=7VXQJB_HH-w&t=2s

Nine clinical studies are running, according to Bancel. Moderna's filings list trials in melanoma, lung, bladder, and kidney cancers.

He said the messenger RNA (mRNA) shot prompts the body to make new T cells, which fight tumors. Keytruda, Merck's immunotherapy, instead revives exhausted ones.

Why Did Shares Slip on a Positive Result?

Researchers presented full Phase 3 data at the European Society for Medical Oncology (ESMO) congress on Oct. 24. However, the trial cut the risk of distant spread or death by 38%. In contrast, an earlier midstage study showed a 62% reduction at three years.

Despite the positive news, expectations were high, and the stock price fell. Despite the positive news, expectations were high, and the stock price fell. Source: Trading View

Bancel said early distant-spread numbers trail recurrence figures because cancer takes time to spread. The Phase 3 also enrolled earlier-stage patients, he noted.

The data leaked two days earlier, on Oct. 22, coinciding with Moderna's leak-day slide. Bancel said the leak appeared not to come from Moderna or Merck, pointing to ESMO's embargo talks with other outlets. That claim remains unverified.

Meanwhile, pricing remains undisclosed, and Bancel said a Food and Drug Administration filing comes before insurer talks. Moderna and Merck split capital and operating costs 50/50, he said.

The test now shifts from efficacy to economics, meaning what insurers will cover for a dose made per patient. That question also reaches the cancer vaccine diagnostics opportunity, where tumor-sequencing demand could depend on these therapies scaling.

Read the Original story Moderna CEO Says Cancer Vaccine Could Work Beyond Melanoma But Shares Still Slip by Darryn Pollock at beincrypto.com